UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 4, 2020

MORPHIC HOLDING, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-38940

(Commission

File Number)

Delaware (State or other jurisdiction of incorporation or organization)

> 35 Gatehouse Drive, A2 Waltham, MA (Address of principal executive offices)

47-3878772 (I.R.S. Employer Identification No.)

02451 (Zip Code)

(781) 996-0955

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

	Trading	
Title of each class	Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	MORF	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company \boxtimes

If an emerging grown company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

Morphic Holding, Inc. presented the investor presentation attached hereto as Exhibit 99.1 at the Cowen Healthcare Conference on March 4, 2020.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits

Exhibit Number

<u>99.1</u>

Morphic Investor Presentation

Description

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 4, 2020

MORPHIC HOLDING, INC.

By: /s/ Robert E. Farrell, Jr.

Robert E. Farrell, Jr. Senior Vice President of Finance and Chief Accounting Officer

3



DELIVERING A NEW GENERATION OF INTEGRIN MEDICINES

Praveen Tipirneni, MD Cowen 40th Annual Healthcare Conference March 4th, 2020




Forward Looking Statements

This presentation contains "forward-looking" statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Morphic's plan to develop and commercialize oral small-molecule integrin therapeutics and Morphic's expectations about timing and ability to obtain regulatory approvals for MORF-720, MORF-057, and other candidates in development and the sufficiency of our cash, cash equivalents and investments to fund our operations. Statements including words such as "believe," "plan," "continue," "expect," "will be," "develop," "signal," "potential," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forwardlooking statements are subject to risks and uncertainties that may cause Morphic's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Morphic's ability to develop, obtain regulatory approval for and commercialize MORF-720, MORF-057, and other product candidates, the timing and results of preclinical studies and clinical trials, Morphic's ability to protect intellectual property; and other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Morphic specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Adaptability to Dynamic Environments is the Human Story – and the Story of Integrins







Unique Opportunity to Mine Integrins: Well Validated Target Class

Validated Target Class with Large Market Opportunity	 All approved integrin therapies are non-oral options for a wide variety of serious chronic diseases Estimated 2018 sales of at least \$4.6 billion¹
THE Integrin Platform	 Leveraging proprietary databases, world-class know-how and decades of Springer laboratory research Designed to target and modulate every known human integrin
Potential First-in- Class Pipeline	 Oral integrin therapies have historically failed in development due to poorly understood biology Morphic's goal: deliver the first generation of approved oral integrin drugs in IBD, fibrosis and other indications
Tansformational Partnerships	 AbbVie (\$100 million upfront); Morphic eligible for enhanced royalties in liver fibrosis with opt in Janssen (up to \$729 million in milestones in addition to potential royalties)
Strong Cash Position	• YE 2019 cash position: \$237 million, through at least 2022
bal Data DENTIAL	



5

Morphic Integrin Technology (MInT) Platform





6

Morphic: Focused on Major Chronic Conditions

Development Pipeline Status **Our Programs** Indication Discovery Preclinical IND Phase 1 **Product Rights** MORF-057 Inflammatory bowel Wholly Owned disease (IBD) Target: $\alpha_4\beta_7$ MORF-720 Idiopathic pulmonary abbvie fibrosis $\mathsf{Target:} \alpha_v \beta_6$ $MR\,\beta_6\,\#2$ Primary Sclerosing Morphic/AbbVie Target: $\alpha_v \beta_6$ Cholangitis


Research Pipeline

Focus	$\alpha_\nu\beta_1 \text{ inhibition for fibrotic} \\ \text{disease}$	TGF-β activation for solid tumors	TGF-β activation for fibrotic disease	Undisclosed targets, including αl domain integrins
Collaborator	Wholly owned	Wholly owned	abbvie	Janssen 🕇






$\alpha_4\beta_7$: A Proven Mechanism of Action in IBD






MORF-057: Pre-clinical Data Dose-dependent Anti-inflammatory Activity



• p<0.05, ** p<0.01, ***p<0.001, and ****p<0.0001 vs. vehicle by One Way Anova followed by Dunnett's multiple comparisons • DATK32 is a mouse surrogate of the $\alpha_4\beta_7$ antibody vedolizumab

MORF-057: Specifically Designed to be Highly Selective for $a_4\beta_7$



CONFIDENTIAL

Presented at ECCO'20 Vienna Congress by Jamie Wong, Morphic Therapeutic




MORF-057: Specifically Designed to be Highly Selective for $a_4\beta_7$




Leukocyte	Inhibitor	α ₄ β ₇ IC ₅₀ RPMI8866 MADCAM	α ₄ β ₁ IC ₅₀ Jurkat VCAM	α ₄ β ₁ IC ₅₀ RPMI8866 VCAM	Fold selectivity
α ₄ β ₁ α ₄ β ₇	MORF-057	1.2 nM	>50 uM	3,600 nM	≥3,000
u ₄ p ₇	Vedolizumab	0.06 nM	>180 nM	>48 nM	>3,000
	Natalizumab	0.15 nM	1.8 nM	0.14 nM	1-12
MORF-057	AJM300	140 nM	4,200	770 nM	5-30
VCAM-1 Inhibiting VCAM-1 brings risk of PML Endothelial cell	adhesion a magnitude • MORF-057	is highly sel ssays in 50%) has high sel	ective for α ₄ human seru ectivity agai on assays wi	um (over 3 o	erders of
	Preser	nted at ECCO'20 V	enna Congress by	Jamie Wong, Mor	phic Therapeutic

CONFIDENTIAL

11






MORPHIC




MORF-057 Goal: Oral Vedolizumab

In addition to later-stage treatment, an oral option could intervene much earlier in disease progression




CONFIDENTIAL

13






$\alpha_{\nu}\beta_{\delta}$: Essential Activator of TGF- β Signaling





Morphic Oral $\alpha_{\nu}\beta_{6}$ Inhibitor: Strong Support for Mechanism of Action and Design


- MORF-720 delivers dose-dependent reductions in liver fibrosis in mice model
- Shown to stabilize closed conformation of $\alpha_{\nu}\beta_{6}$
- Excellent multi-species PK
- Highly potent and selective




 p<0.05, ** p<0.01, ***p<0.001, and ****p<0.0001 vs. vehicle by One Way Anova followed by Dunnett's multiple comparisons

Morphic Oral Integrin Inhibitor: Activity in Anti- $\alpha_{\rm v}\beta_{\rm 6}\,mAb$ in Collagen Model of Fibrosis





Morphic Oral Integrin Inhibitor: Superior in Bilirubin Model of Fibrosis



18

MORPHIC



19

Building the Future of Integrin Medicines

Deep specialist expertise across management, Board and Advisors BLAISE LIPPA, PhD PRAVEEN TIPIRNENI, MD BRUCE ROGERS, PhD ALEXEY A. LUGOVSKOY, PhD ADRIAN RAY, PhD WILLIAM DeVAUL President and Chief Executive Officer **Chief Scientific Officer Chief Development Officer** Head of Chemistry **Head of Translational Sciences General** Counsel and Secretary M merrimack Biogen CUBIST GILEAD PHARMACIA Pfizer Pfizer MEVELO CUBIST CUBIST Well capitalized, partnered and poised to advance oral integrins .

Launch	Series A \$51 M	Series B \$80M	abb∨ie \$100M	Janssen 📕 \$10M	1PO \$103.5M ¹	Planned clinical trials in 2020	
•	•	•	•	•	•		
Aug 2015	Jun 2016	Sep 2018	Oct 2018	Feb 2019	Jun 2019	YE19 Cash: \$237 million	

¹\$103.5M gross proceeds before fees CONFIDENTIAL



20

THANK YOU